AdipoGenix, Inc. is a Boston-based biopharmaceutical company developing small molecule pharmaceuticals to treat obesity and its co-morbidities. Obesity is too much fat, and the pharmacologic target for our drug discovery programs is human fat tissue. Our core assets and competencies have been discovered and developed with the guidance of our founders who are internationally recognized leaders in the field of obesity research. These assets and capabilities include a proprietary and diverse collection of human fat cell precursors from all relevant human fat depots, a high-throughput discovery technology for identifying compounds that reduce the fat content of human fat, a portfolio of assays and pharmacologic tools to identify the mechanism of action and molecular targets for active compounds identified, and proprietary lead compounds. Through our proprietary human fat cell-based discovery technology, we have identified nontoxic cellular-active small molecule compounds that:

  1. Reduce the number of mature fat cells formed from precursor cells,
  2. Decrease the synthesis and storage of fat in mature fat cells,
  3. Increase the breakdown and release of stored fat, and
  4. Enhance the burning of stored fat to produce energy.

Our approach to treating obesity by targeting human fat with pharmaceuticals that reduce fat content is distinctive, our human fat cell-based discovery technology is unique, and we believe this combination will provide safe, efficacious therapeutics for combating the growing obesity epidemic.